Diagrammatic illustration of the mechanism of two monoclonal antibodies utilized for treating eosinophilic asthma, mepolizumab, and benralizumab. Mepolizumab specifically targets interleukin-5 (IL-5), ...

Please provide your email address to receive an email when new articles are posted on . Clinical remission meant no exacerbations, no maintenance oral corticosteroid use and well-controlled asthma. A ...

Please provide your email address to receive an email when new articles are posted on . Benralizumab was favored over placebo when assessing risk for hypereosinophilic syndrome flares. Benralizumab ...